Newsroom_PressReleases_subhead

In the news

Press releases

Stories

Prime Insights

Media resources

Section divider

   2018

2018

2017

2016

2015

Prime Therapeutics moves into new Eagan “home”

Phase 1 complete, Phase 2 underway; Nearly 400,000 square foot facility to eventually house four of Prime’s Minnesota offices. More about the facility


Prime Therapeutics’ diabetes drug therapy study: Multi-stakeholder improvement needed to help patients stay on, use most clinically appropriate drugs to prevent cardiovascular events

Real world evidence shows poor persistency to diabetes drug therapy. More about the study


Prime Therapeutics finds different predictive models are needed to identify future high-risk prescription opioid use for new versus current opioid users

Different factors predict an individual’s risk for future high dose opioids. More about this research


Providing Opioid Safety Guide at the pharmacy counter associated with four-fold increase in overdose reversal drug dispensing

Florida Blue, Prime Therapeutics and Walgreens pilot project to address opioid epidemic confirms power of collaboration. More about the pilot project


Prime Therapeutics inks value-based contract for Stelara® with Janssen

Medical and pharmacy claims data will track how long patients stay on Stelara®, informing Prime’s clinical programs aimed at better health outcomes. More about the contract


Prime Therapeutics applauds congressional bodies for action on gag clauses 

Prime commends the House Energy and Commerce Committee and the Senate for voting to end practices that prohibit pharmacists from telling members they can save money by paying cash rather than using their insurance plan. Statement


Prime Therapeutics statement on CMS’ decision to allow indication-based formulary design  

New program begins in 2020 and focuses on formularies that cover specific drugs for specific indications. Statement


Prime Therapeutics Signs Risk-Share Agreement for Immunology Drug Cosentyx®

Contract measures persistence to medication, helps control costs for payer clients and members. More about the agreement


Prime Therapeutics names Michael Looney senior vice president, government programs

Looney is responsible for growth and retention in the Medicare, federal and Medicaid segments of our business. More about his experience


Matt Pammer appointed as Prime Therapeutics’ Chief Information Officer

Matt brings with him a wealth of IT experience in the pharmaceutical industry and client focus, which makes him a great fit for Prime. More about his experience


Prime Therapeutics expands its Fraud, Waste, Abuse detection to include prescribers, patients  

New agreement to deploy SAS’® analytics software tool allows for comprehensive FWA identification. More about the agreement


Prime Therapeutics‘ statement regarding President Trump’s plan to lower prescription drug prices 

Prime stands ready to apply the momentum of our past 20 years to address the new opportunities and challenges that lie ahead. Statement


Two Prime Therapeutics programs associated with improved adherence for Medicare members using cholesterol, diabetes and hypertension drugs 

Lower generic cost share, missed refill interventions may yield better health, higher Star Ratings. Read about this research


Prime Therapeutics finds drug’s additional use for myasthenia gravis may significantly impact trend 

Analyzing integrated medical, pharmacy drug claims essential in forecasting eculizumab’s (Soliris®) cost. Read more about this research


Prime Therapeutics finds poor adherence to high-cost Multiple Sclerosis therapy 

Disease-modifying drugs produce significantly fewer relapses, cost-effectiveness in question. Read more about two studies.


Prime Therapeutics finds costs double when switching to new extended half-life hemophilia factor products 

Real-world data analysis shows extended half-life coagulation factor products bring high cost. Read more about these research findings


Prime Therapeutics finds drug costs drive nearly entire cost of care for hereditary angioedema 

Care management is key to better health outcomes, medication cost savings. Read more about these research findings


Prime Therapeutics Receives PBMI’s Excellence Award 

Controlled Substance Management Program recognized for helping to reduce opioid epidemic. More about the award | More about Prime's Controlled Substance Management Program


Prime Therapeutics surpasses 1 million Medicaid members

Growth is a result of client collaboration, dedication to quality outcomes and affordability. More about why this growth is so important.


Prime Therapeutics proves PBMs’ value: Delivers negative drug trend in 2017

Prime’s PBM tools provided much needed cost relief. Drug trend results


Prime Therapeutics and Boehringer Ingelheim Enter Into Outcomes-Based Contract for Jardiance®

New CareCentered ContractingTM agreement integrates pharmacy and medical claims data to evaluate member outcomes. More


Prime Therapeutics pharmacist elected to Academy of Managed Care Pharmacy Board of Directors

Patrick Gleason, PharmD, to serve 2-year term. More about Pat and AMCP